H2BC5

Across TCGA pan-cancer cohorts, H2BC5 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated H2BC5 data layer compared with 21 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher H2BC5 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated H2BC5 expression acts as an unfavorable survival marker, although some lineages such as BLCA show a favorable association.

LUSC, OV, and LUAD are the cancer types where H2BC5 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	III,IV	0.086	0.684	<.001	24	view →
OV	DFS	Median	All	0.160	0.541	.003	18	view →
LUAD	DFS	Median	II,III,IV	0.161	0.684	<.001	18	view →
COAD	DFS	Median	II,III,IV	0.219	0.666	.002	12	view →
LIHC	DFS	Median	All	0.083	0.553	.009	12	view →
BLCA	DFS	Median	All	0.802	0.503	.041	5	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

H2BC5–LUSC (OS)

Open the LUSC breakdown →